AZ licenses Heptares' immuno-oncology candidate

The Heptares Therapeutics Ltd. subsidiary of Sosei Group Corp. (Tokyo:4565) granted an exclusive, worldwide license to adenosine A2A ( ADORA2A) receptor inhibitor HTL1071 to AstraZeneca plc (LSE:AZN; NYSE:AZN).

AZ will pay $10 million up front for rights to the immuno-oncology candidate and other preclinical A2A receptor inhibitors. ...